3 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 3 Phase 1, 3 Phase 2, 3 Phase 3, 1 Phase 4.
Follow BCG Solution: new trials by email Literature Review of BCG Solution trials Research Report on BCG Solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer Accelerometry, BCG Solution, Electronic Health Record Review - Non-Muscle Invasive Bladder Carcinoma | Phase 4 | Recruiting | Ohio State University Comprehensive Cancer Center | 40 | 2026-02-26 | 2026-03-16 |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy BCG Solution, Biopsy of Bladder, Cystoscopy - Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 330 | 2025-07-17 | 2026-10-02 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial BCG Solution, Cystoscopy, Docetaxel - Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 40 | 2025-04-21 | 2026-10-08 |
| Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer Acupuncture Therapy, BCG Solution, Best Practice - Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 45 | 2021-01-22 | 2024-01-02 |
| S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine - Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 1000 | 2017-02-24 | 2026-03-23 |
| Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab - Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma | Phase 1 | Completed | Northwestern University | 9 | 2017-02-10 | 2024-06-26 |
| Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer BCG solution, recombinant interferon alfa, epirubicin hydrochloride - Bladder Cancer | Phase 3 | Unknown | Cancer Research Campaign Clinical Trials Centre | 242 | 2009-10-01 | 2013-08-12 |
Urinary Bladder Neoplasms (5) · Non-Muscle Invasive Bladder Neoplasms (4)
Ohio State University Comprehensive Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Cancer Research Campaign Clinical Trials Centre (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · Northwestern University (1) · SWOG Cancer Research Network (1)
United States (7) · United Kingdom (1)
Cheryl T Lee, MD (2) · Eugene Pietzak, MD (1) · John Kelly, MD (1) · Joshua Meeks (1) · Robert Svatek (1) · Sarah P. Psutka (1) · Timothy D. Lyon, MD (1)
PMID 30197040, PMID 30274699, PMID 36008193, PMID 42821609
P30CA015704 (1), P30CA060553 (1), U10CA180888 (1), UL1TR002377 (1)